4893 items matching your search terms.

Results of the quad wild type arm of the AGITG ICECREAM study: a randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA

Shapiro, J.D. Thavaneswaran, S. Underhill, C. Robledo, K.P. Karapetis, C.S. Day, F.L. Nott, L.M. Jefford M. Chantrill, L.A. Pavlakis, N. Tebbutt, N.C. Price, T.J. Khasraw, M. Van Hazel, G. Waring, P.M. Tejpar, S. Simes, J. Gebski, V. Desai, J. Segelov, E.

Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy in patients with liver metastases from colorectal cancer

Sharma, R. Wasan, H.S. Van Hazel, G.A. Heinemann, V. Sharma, N.K. Taieb, J. Ricke, J. Mills, J. Tait, N.P. Boardman, P. Peeters, M. Findlay, M.P.N. Virdee, P.S. Moschandreas, J. Gebski, V. Love, S. Gray, A. Gibbs, P.

Targeted LOWering of Central Blood Pressure in patients with hypertension: baseline recruitment, rationale and design of a randomized controlled trial (The LOW CBP study)

Sharman, J. E. Stanton, T. Reid, C. M. Keech, A. Roberts-Thomson, P. Stewart, S. Greenough, R. Stowasser, M. Abhayaratna, W. P.
CONTEMPORARY CLINICAL TRIALS, 2017     DOI:10.1016/j.cct.2017.08.010

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): the IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration

Shi, Q. Sobrero, A. F. Shields, A. F. Yoshino, T. Paul, J. Taieb, J. Sougklakos, I. Kerr, R. Labianca, R. Meyerhardt, J. A. Bonnetain, F. Watanabe, T. Boukovinas, I. Renfro, L. A. Grothey, A. Niedzwiecki, D. Torri, V. Andre, T. Sargent, D. J. Iveson, T.
, 2017     DOI:10.1200/JCO.2017.35.18_suppl.LBA1

Integrate II: a randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer—an international study organized by the Australasian Gastrointestinal Trials Group

Sjoquist, K.M. Pavlakis, N. Martin, A.J. Tsobanis, E. Yip, S. Bang, Y.J. Alcindor, T. O'Callaghan, C.J. Shitara, K. Bekaii-Saab, T.S. Grothey, A. Chen, L.T. Simes, J. Zalcberg, R. Goldstein, D.

Personalizing survival predictions in advanced colorectal cancer: the ARCAD nomogram project

Sjoquist, K. M. Renfro, L. A. Simes, R. J. Tebbutt, N. C. Clarke, S. Seymour, M. T. Adams, R. Maughan, T. S. Saltz, L. Goldberg, R. M. Schmoll, H. J. Van Cutsem, E. Douillard, J. Y. Hoff, P. M. Hecht, J. R. Tournigand, C. Punt, C. J. A. Koopman, M. Hurwitz, H. Heinemann, V. Falcone, A. Porschen, R. Fuchs, C. Diaz-Rubio, E. Aranda, E. Bokemeyer, C. Souglakos, I. Kabbinavar, F. F. Chibaudel, B. Meyers, J. P. Sargent, D. J. de Gramont, A. Zalcberg, J. R. Fondation Aide et Recherche en Cancerologie Digestive, Group
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017     DOI:10.1093/jnci/djx253

A pilot randomized controlled trial of the feasibility, acceptability, and impact of giving information on personalized genomic risk of melanoma to the public

Smit, A. K. Espinoza, D. Newson, A. J. Morton, R. L. Fenton, G. Freeman, L. Dunlop, K. Butow, P. N. Law, M. H. Kimlin, M. G. Keogh, L. A. Dobbinson, S. J. Kirk, J. Kanetsky, P. A. Mann, G. J. Cust, A. E.
CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION, 2017     DOI:10.1158/1055-9965.EPI-16-0395

Does personalized melanoma genomic risk information trigger conversations about skin cancer prevention and skin examination with family, friends and health professionals?

Smit, A. K. Keogh, L. A. Newson, A. J. Butow, P. N. Dunlop, K. Morton, R. L. Kirk, J. Espinoza, D. Cust, A. E.
BRITISH JOURNAL OF DERMATOLOGY, 2017     DOI:10.1111/bjd.15744

OSCILLATE: Phase 2 trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation-positive advanced NSCLC

Solomon, B. Kok, P. S. Livingstone, A. Yip, S. Brown, C. Dawson, S.J. Wong, W. Pavlakis, N. Stockler, M.R.

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: subgroup analysis of the randomised phase III AURELIA trial

Sorio, R. Roemer-Becuwe, C. Hilpert, F. Gibbs, E. Garcia, Y. Kaern, J. Huizing, M. Witteveen, P. Zagouri, F. Coeffic, D. Luck, H. J. Gonzalez-Martin, A. Kristensen, G. Levache, C. B. Lee, C. K. Gebski, V. Pujade-Lauraine, E. Aurelia Investigators
GYNECOLOGIC ONCOLOGY, 2017     DOI:10.1016/j.ygyno.2016.11.006

PICO confirmation 1493 - Transarterial radioembolisation with yttrium-90 (TARE-Y) for the treatment of unresectable hepatocellular carcinoma

Staub, L.

Persistent psychological distress and mortality in patients with stable coronary artery disease

Stewart, R. A. H. Colquhoun, D. M. Marschner, S. L. Kirby, A. C. Simes, J. Nestel, P. J. Glozier, N. O'Neil, A. Oldenburg, B. White, H. D. Tonkin, A. M. Lipid Study Investigators
HEART, 2017     DOI:10.1136/heartjnl-2016-311097

Barriers to radiotherapy utilization: consumer perceptions of issues influencing radiotherapy-related decisions

Sundaresan, P. King, M. Stockler, M. Costa, D. Milross, C.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017     DOI:10.1111/ajco.12579

Immune checkpoint inhibitors in gliomas

Tan, A. C. Heimberger, A. B. Khasraw, M.
CURRENT ONCOLOGY REPORTS, 2017     DOI:10.1007/s11912-017-0586-5

Striking the balance between primary prevention of allergic disease and optimal infant growth and nutrition

Tan, J. W. Turner, P. J. Valerio, C. Sertori, R. Barnes, E. H. Campbell, D. E.
PEDIATRIC ALLERGY AND IMMUNOLOGY, 2017     DOI:10.1111/pai.12775